Post hoc matching-adjusted indirect comparison in treatment-naive CLL/SLL: zanubrutinib (SEQUOIA) was associated with longer investigator-assessed PFS than acalabrutinib-venetoclax (AMPLIFY): 3-year PFS 84.3% vs 78.9%; unadjusted HR 0.45.
Secondary analysis
Shadman et al. An indirect comparison of zanubrutinib vs acalabrutinib plus venetoclax in patients with treatment-naive CLL